In mice bearing B16/OVA tumor and treated by intratumoral injection of α-gal glycolipids, the number of SIINFEKL specific CD8+ T cells was found to be several fold higher than in mice receiving intratumoral injection of PBS. The gene discussed is CD8A; the disease is neoplasm.